Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492901 | 0.91 | MAPK1 (0.67) | MAPK1CHRNA7SMN1; SMN2KDM4EMAPT | |
| SCHEMBL4918783 | 0.88 | MAPK1 (0.60) | MAPK1CHRNA7SMN1; SMN2KDM4EMAPT | |
| SCHEMBL6071579 | 0.87 | CHRNA7 (0.63) | MAPK1CHRNA7SMN1; SMN2MAPTNPC1 | |
| SCHEMBL5922316 | 0.86 | CHRNA7 (0.58) | MAPK1CHRNA7KDM4EMAPTRAB9A | |
| SCHEMBL14270596 | 0.82 | CNR1 (0.53) | MAPK1CHRNA7SMN1; SMN2KDM4EMAPT | |
| SCHEMBL4918803 | 0.77 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL16403251 | 0.77 | CHRNA7 (0.81) | MAPK1CHRNA7MAPTALDH1A1LMNA | |
| SCHEMBL4465707 | 0.76 | NOTUM (0.63) | MAPK1CHRNA7SMN1; SMN2TSHRCNR1 | |
| SCHEMBL5922363 | 0.75 | MAPK1 (0.60) | MAPK1CHRNA7SMN1; SMN2KDM4EMAPT | |
| SCHEMBL4474686 | 0.75 | CHRNA7 (0.62) | CHRNA7CNR1CNR2ALDH1A1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008151389-A1 | CHEMICALLY MODIFIED MACROMOLECULES | MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2008-12-18 | — | — | WO | disclosed |
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | ASTRAZENECA (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | ASTRAZENECA (SE) | 2008-02-28 | — | — | US | disclosed |
| EP-1718610-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080328-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | PC, GPR119, PGC | MAPK1 3403/4885CHRNA7 590/4885SMN1; SMN2 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.